Radiotherapy Market Size & Growth Forecast 2027–2036, By Segments (Type, End Use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Radiotherapy Market size stood at USD 8.09 Billion in 2026 and is predicted to grow at 6.36% CAGR from 2027 to 2036, surpassing USD 14.99 Billion by 2036. The industry revenue for 2027 is estimated at USD 8.53 Billion.

• Base Year Value (2026): USD 8.09 Billion
• CAGR (2027-2036): 6.36%
• Forecast Year Value (2036): USD 14.99 Billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Radiotherapy Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads due to advanced oncology infrastructure, broad access to sophisticated radiation technologies, and substantial healthcare investment supporting precision-based cancer care.
  • Asia Pacific is the fastest-growing region, supported by rising cancer burden, improving healthcare infrastructure, expanding treatment facilities, and greater investment in advanced oncology services.

• Segment Momentum:

  • External Beam Radiation Therapy accounted for 62.3% of the market in 2025 due to broad clinical use, advanced treatment planning, and its ability to deliver precise radiation while minimizing damage to healthy tissues.
  • Prostate cancer is projected to be the fastest-growing application as advanced radiation techniques enable more precise treatment, fewer side effects, and greater adoption of non-invasive cancer therapies.

• Market Expansion Drivers:

  • Rising global cancer incidence driving sustained demand for advanced radiotherapy treatments
  • Technological advancements in precision radiotherapy improving treatment accuracy and outcomes
  • Expanding oncology infrastructure and healthcare investments enabling wider radiotherapy access in emerging markets

• Leading Market Participants:

  Leading companies in the radiotherapy market include Elekta AB (Sweden), Accuray Incorporated (United States), Brainlab AG (Germany), Canon Medical Systems Corporation (Japan), Mitsubishi Electric Corporation (Japan), Toshiba Energy Systems & Solutions Corporation (Japan), Mevion Medical Systems, Inc. (United States), RefleXion Medical, Inc. (United States), Ion Beam Applications S.A. (Belgium)

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 8.09 Billion
  • 2027 Estimated Market Size: USD 8.53 Billion
  • Projected Market Size: USD 14.99 Billion by 2036
  • Growth Forecasts: 6.36% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: External Beam Radiation Therapy (Type) | Hospitals (End Use) | Breast Cancer (Application)
  • Emerging Opportunity Segment: Systemic Radiation Therapy (Type) | Radiotherapy Centers and Ambulatory Surgery Centers (End Use) | Prostate Cancer (Application)

Market Growth Drivers and Industry Trends

Rising global cancer incidence driving sustained demand for advanced radiotherapy treatments

The increasing prevalence of cancer worldwide is creating sustained demand for effective treatment options, making the radiotherapy market an essential component of modern oncology care. Radiotherapy remains a widely utilized treatment approach for multiple cancer types, either as a standalone therapy or in combination with surgery, chemotherapy, and immunotherapy. As healthcare providers manage growing patient volumes, the need for advanced radiation treatment systems capable of delivering effective and individualized therapies continues to expand across healthcare settings.

Technological advancements in precision radiotherapy improving treatment accuracy and outcomes

Continuous innovation in radiation delivery technologies is improving clinical precision and treatment effectiveness, which will propel the radiotherapy market growth. Advanced imaging integration, treatment planning software, adaptive therapy techniques, and highly targeted radiation delivery enable clinicians to focus therapeutic doses more accurately while minimizing exposure to surrounding healthy tissues. These technological improvements support personalized treatment strategies and enhance the ability of healthcare providers to manage complex oncology cases with greater confidence.

Expanding oncology infrastructure and healthcare investments enabling wider radiotherapy access in emerging markets

Growing investments in healthcare infrastructure and specialized oncology services are strengthening access to cancer treatment, and the radiotherapy market is benefiting from broader availability of advanced therapeutic capabilities in emerging economies. The establishment of dedicated cancer centers, modernization of hospital facilities, and expansion of radiation treatment capacity are improving access for larger patient populations. These developments are also encouraging the adoption of modern radiotherapy systems supported by trained clinical professionals and integrated cancer care services.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising global cancer incidence driving sustained demand for advanced radiotherapy treatments	2%	High	North America, Europe	High	Near Term
Technological advancements in precision radiotherapy improving treatment accuracy and outcomes	1.8%	High	Europe, Asia Pacific	High	Mid Term
Expanding oncology infrastructure and healthcare investments enabling wider radiotherapy access in emerging markets	1.6%	High	Asia Pacific, Latin America	High	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest position in the radiotherapy market in 2026, supported by advanced oncology infrastructure, broad access to sophisticated radiation treatment technologies, and substantial healthcare investment. The region's established network of cancer treatment centers and increasing emphasis on precision-based cancer care are strengthening the adoption of advanced radiotherapy approaches. Growing demand for minimally invasive and targeted treatment options, combined with improvements in treatment planning and radiation delivery, is also supporting regional market development. Continued investment in healthcare technology and the expansion of specialized cancer care capabilities are expected to reinforce North America's market position.

Asia Pacific is anticipated to register the fastest growth, driven by the rising cancer burden, improving healthcare infrastructure, and increasing investment in advanced oncology services. Growing healthcare expenditure and the expansion of specialized treatment facilities are improving access to radiotherapy across emerging healthcare markets. In addition, greater awareness of cancer screening and treatment, government efforts to strengthen cancer care capacity, and the gradual adoption of technologically advanced radiation treatment systems are creating favorable conditions for regional expansion.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

Type Segment Analysis: External Beam Radiation Therapy (Largest Segment) vs Systemic Radiation Therapy (Fastest-Growing Segment)

External beam radiation therapy dominated the radiotherapy market and accounted for 62.3% of the market share in 2026. Its leading position is supported by widespread clinical adoption across multiple cancer indications, the availability of advanced treatment planning technologies, and its ability to deliver highly targeted radiation while minimizing damage to surrounding healthy tissues. Continuous improvements in imaging guidance, treatment precision, and workflow efficiency have further strengthened its role as the standard approach in modern radiation oncology.

The systemic radiation therapy segment is expected to witness the fastest growth as targeted radiopharmaceutical therapies gain wider acceptance for treating specific cancers. Ongoing advancements in precision medicine, increasing emphasis on personalized treatment strategies, and the growing availability of targeted radioactive agents are expanding the clinical application of systemic therapies. Their ability to selectively target cancer cells while complementing other treatment modalities is expected to support continued adoption.

End Use Segment Analysis: Hospitals (Largest Segment) vs Radiotherapy Centers and Ambulatory Surgery Centers (Fastest-Growing Segment)

The hospitals segment held the largest share of 44.41% in 2026. Hospitals remain the primary providers of radiotherapy services because they offer comprehensive oncology care supported by multidisciplinary medical teams, advanced imaging capabilities, and access to sophisticated radiation treatment systems. Their ability to manage complex cancer cases while integrating surgery, chemotherapy, and radiation therapy within a single healthcare setting continues to reinforce their market leadership.

In the radiotherapy market, radiotherapy centers and ambulatory surgery centers are anticipated to register the fastest growth. Rising demand for specialized cancer treatment facilities, shorter patient waiting times, and greater accessibility to outpatient oncology services are encouraging patients and healthcare providers to utilize dedicated treatment centers. Continued investments in advanced radiotherapy equipment and the expansion of specialized oncology networks are expected to accelerate growth within this segment.

Application Segment Analysis: Breast Cancer (Largest Segment) vs Prostate Cancer (Fastest-Growing Segment)

The breast cancer segment led the radiotherapy market and captured 31.1% of the market share in 2026. Radiotherapy remains an essential component of breast cancer treatment following breast-conserving surgery and in selected post-mastectomy cases, helping reduce recurrence while improving long-term treatment outcomes. Greater awareness, widespread screening initiatives, and established clinical treatment protocols continue to sustain strong demand for radiotherapy in breast cancer management.

The prostate cancer segment is projected to experience the fastest growth due to increasing adoption of advanced radiation techniques that enable precise dose delivery while minimizing side effects. Growing preference for non-invasive treatment options, expanding availability of image-guided and intensity-modulated radiotherapy, and increasing diagnosis among aging populations are contributing to stronger utilization of radiotherapy for prostate cancer care.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type	External Beam Radiation Therapy, Internal Radiation Therapy, Systemic Radiation Therapy	External Beam Radiation Therapy	Systemic Radiation Therapy
End Use	Hospitals, Radiotherapy Centers and Ambulatory Surgery Centers, Cancer Research Institutes	Hospitals	Radiotherapy Centers and Ambulatory Surgery Centers
Application	Lung Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head and Neck Cancer, Others	Breast Cancer	Prostate Cancer

Competitive Landscape and Market Positioning

Major players in the radiotherapy market:

1. Elekta AB (Sweden)
2. Accuray Incorporated (United States)
3. Brainlab AG (Germany)
4. Canon Medical Systems Corporation (Japan)
5. Mitsubishi Electric Corporation (Japan)
6. Toshiba Energy Systems & Solutions Corporation (Japan)
7. Mevion Medical Systems, Inc. (United States)
8. RefleXion Medical, Inc. (United States)
9. Ion Beam Applications S.A. (Belgium)

The radiotherapy market is experiencing a competitive transition as providers focus on advancing treatment precision, workflow efficiency, and patient-specific care capabilities. Differentiation is increasingly driven by the ability to integrate sophisticated imaging, treatment planning, and delivery technologies that improve clinical outcomes while addressing the operational demands of modern oncology centers. Market participants with strong expertise in developing comprehensive radiation therapy ecosystems are strengthening their positions, while specialized innovators are targeting opportunities through focused solutions for complex treatment applications. The competitive environment is also being influenced by the growing need for systems that support automation, reduce treatment complexity, and enable broader access to advanced cancer care.

Industry Development/News

Company Name	Date	Key Development
Leo Cancer Care	Jul-26	Leo Cancer Care secured $65 million in financing to accelerate the commercialization of its upright radiotherapy system. The company also entered a strategic partnership with an international healthcare company ahead of a planned public listing.
United Imaging	May-26	United Imaging received CE Mark approval for its CT-linac system. The regulatory milestone and presentation of its full portfolio at ESTRO 2026 support the company's geographic and commercial expansion into the European radiotherapy market.
Institut Curie	Mar-25	Institut Curie initiated patient treatments utilizing a new MRI-Linac adaptive radiotherapy system. The deployment is part of a €56 million capital investment program designed to scale the institution's advanced radiation therapy infrastructure.
Novartis	Sep-24	Novartis expanded its production infrastructure by establishing in-house isotope manufacturing and constructing a new West Coast facility. The expansion secures the supply chain and delivery capacity for its targeted radiopharmaceutical portfolio.
Elekta	May-24	Elekta expanded its software intellectual property through the acquisition of Philips Healthcare's Pinnacle Treatment Planning System patent portfolio. The transaction enhances Elekta's capabilities in radiation therapy treatment planning software.
Nucleus RadioPharma	May-24	Nucleus RadioPharma entered a manufacturing partnership with ARTBIO to produce a clinical-stage prostate cancer radiopharmaceutical candidate. The agreement expands specialized contract manufacturing footprint within the targeted radiotherapy segment.
MIM Software	Apr-24	GE Healthcare's subsidiary, MIM Software, expanded its collaboration with Elekta AB to co-develop advanced radiation therapy software. This initiative deepens their previous hardware-focused hospital supply agreement into digital oncology workflows.
Affidea	Mar-24	Affidea acquired a Romanian radiotherapy provider operating four regional cancer care locations. The acquisition expands Affidea's healthcare service network and solidifies its clinical oncology market share in Eastern Europe.
Novartis	Jan-24	Novartis secured U.S. FDA approval for its Indianapolis production facility. The regulatory clearance permits commercial manufacturing of Pluvicto, significantly expanding the company's radiopharmaceutical production capacity.